UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Fax: +44 (0) 1773 810644
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123
Summary of Product Characteristics last updated on the eMC: 29/09/2009
SPC Predsol Suppositories

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 29/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



·         the additional warning "Use with caution in patients with myasthenia gravis, non-specific ulcerative colitis, diverticulitis, fresh intestinal anastamoses" to section 4.4 of the SPC.

·         section 4.5 of the SPC to include interactions with fluoroquinolones, anticholinesterases, licorice and neuromuscular blockers.

·        section 4.8 of the SPC to include undesirable effects: blood and lymphatic system disorders - alteration in lipid levels, leukemoid reactions; ophthalmic - chorioretinopathy; dermatological - dermatitis and toxic epidermal necrolysis.

Updated on 04/04/2008 and displayed until 29/09/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Updated sections 4.4 & 4.8 to include early psychiatric effects associated with corticosteroids
Updated on 31/03/2008 and displayed until 04/04/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Changes to sections 4.4 and 4.8 of SPC to include early psychiatirc effects associated with corticosteroids.

Updated on 15/09/2005 and displayed until 31/03/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 25/06/2003 and displayed until 15/09/2005
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
Updated on 02/07/2001 and displayed until 25/06/2003
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 06/09/1999 and displayed until 02/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   prednisolone sodium phosphate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk